Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$9.35 USD

9.35
4,422,333

-0.26 (-2.71%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ekta Bagri headshot

Biotech Sector in Focus as Coronavirus Spreads Panic

by Ekta Bagri

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Emergent (EBS) Begins Development of Treatments for COVID-19

by Zacks Equity Research

Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.

Kinjel Shah headshot

3 Small Biotechs Provide Coronavirus Drug Development Updates

by Kinjel Shah

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -4.63% and 120.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Emergent BioSolutions Collaborates for Coronavirus Vaccine

by Zacks Equity Research

Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.

Sriparna Ghosal headshot

3 MedTech Stocks to Rebound After Coronavirus-Led Recoil

by Sriparna Ghosal

As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.

5 Drug Makers to Gain From Coronavirus Outbreak

by Zacks Equity Research

Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.

Kinjel Shah headshot

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

by Kinjel Shah

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVAX) Outperforming Other Medical Stocks This Year?

Dropbox, Groupon, QIAGEN, Zoom Video Communications and Novavax highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Dropbox, Groupon, QIAGEN, Zoom Video Communications and Novavax highlighted as Zacks Bull and Bear of the Day

Kinjel Shah headshot

5 Biotechs That Escaped the Coronavirus Onslaught Last Week

by Kinjel Shah

Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Sreyoshi Mukherjee headshot

3 Stocks Are Gaining Even as Coronavirus Creates Chaos

by Sreyoshi Mukherjee

While key players in the United States are struggling to cope, the coronavirus has been a boon for some.

Company News for Feb 27, 2020

by Zacks Equity Research

Companies In The News Are: NVAX,

The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax

4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large

by Zacks Equity Research

Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus

Neena Mishra headshot

Can Biotech ETFs Continue to Soar in 2020?

by Neena Mishra

We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $6.97, marking a -0.57% move from the previous day.

Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Novavax, Inc. (NVAX).

Kevin Cook headshot

Coronavirus: How Fast to 100,000 Infected?

by Kevin Cook

The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

Kevin Cook headshot

Coronavirus: Epidemic or Pandemic?

by Kevin Cook

The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVAX) Outperforming Other Medical Stocks This Year?

Indrajit Bandyopadhyay headshot

CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

by Indrajit Bandyopadhyay

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.